Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) – TMF Reference Model versus the Real-World Study Document Index (RWS-DI)
RWE 101 - TMF Reference Model versus the Real-World Study Document Index (RWS-DI) The Real World Study-Document Index (RWS-DI) is a framework developed by a working group of RWE [...]
Real World Evidence (RWE) 101 – ISF vs TMF
RWE 101 - ISF vs TMF Investigator Site File (ISF) and Trial (Study) Master File (TMF) are key elements in managing clinical and observational studies. They are distinct but [...]
Real World Evidence (RWE) 101 – Study Conduct
RWE 101 - Study Conduct Once the study has been set up, the study conduct phase begins. This phase includes several key activities that ensure the smooth running of [...]
Real World Evidence (RWE) 101 – Monitoring
RWE 101 - Monitoring Monitoring requirements for Real-World Evidence (RWE) studies may differ from those of traditional randomized controlled trials due to the nature of data collection and the [...]
Real World Evidence (RWE) 101 – eConsent
RWE 101 - eConsent Electronic consent or eConsent refers to the process of using electronic systems and processes to convey information related to the study and to obtain and [...]
Real World Evidence (RWE) 101 – Consent to Participate in Research vs Consent to Access and Process Sensitive Healthcare Data (GDPR)
RWE 101 - Consent to Participate in Research vs Consent to Access and Process Sensitive Healthcare Data (GDPR) Consent to participate in research and consent to access and process [...]







